Astria Therapeutics (NASDAQ:ATXS) Sets New 52-Week High – Time to Buy?

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $12.72 and last traded at $12.6150, with a volume of 154274 shares changing hands. The stock had previously closed at $12.62.

Analyst Ratings Changes

Several research firms have recently commented on ATXS. Wedbush set a $13.00 price target on shares of Astria Therapeutics and gave the company a “neutral” rating in a report on Wednesday, October 15th. Citizens Jmp downgraded Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 15th. JMP Securities reaffirmed a “market perform” rating on shares of Astria Therapeutics in a research report on Wednesday, October 15th. Lifesci Capital downgraded Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Finally, Evercore ISI reissued an “outperform” rating and issued a $26.00 price target on shares of Astria Therapeutics in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Astria Therapeutics has a consensus rating of “Hold” and an average price target of $24.50.

Astria Therapeutics Stock Performance

The stock has a 50 day moving average of $11.33 and a two-hundred day moving average of $7.98. The firm has a market capitalization of $748.89 million, a P/E ratio of -6.13 and a beta of 0.07.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The business had revenue of $0.71 million during the quarter, compared to analysts’ expectations of $10.67 million. Sell-side analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ATXS. Russell Investments Group Ltd. grew its position in shares of Astria Therapeutics by 10,311.8% in the third quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 3,506 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Astria Therapeutics by 185.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,557 shares during the last quarter. Brooklyn Investment Group boosted its stake in Astria Therapeutics by 1,079.6% during the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,957 shares during the period. AlphaQuest LLC boosted its stake in Astria Therapeutics by 100.9% during the 1st quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 7,139 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new stake in Astria Therapeutics in the 3rd quarter valued at approximately $98,000. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.